论文部分内容阅读
目的探讨博尔宁胶囊配合化疗治疗胃癌的临床疗效。方法 58例胃癌患者,根据治疗药物的不同将其分为单纯化疗组(28例)和联合组(博尔宁胶囊联合化疗)(30例),比较两组患者近期临床效果、食欲改变以及不良反应发生率等指标。结果经过治疗后发现,联合组患者其近期治疗效果明显优于单纯化疗组(P<0.05);治疗后联合组患者食欲改变情况(76.7%)明显优于单纯化疗组(14.3%)(P<0.05);联合组患者不良反应发生率为53.3%,单纯化疗组患者不良反应发生率为50.0%,联合组患者不良反应发生率高于单纯化疗组,但两组比较差异无统计学意义(P>0.05)。结论博尔宁胶囊配合化疗治疗胃癌其近期临床治疗效果显著,明显改善患者食欲状况,且可有效降低患者不良反应发生率,该方法安全可靠。
Objective To investigate the clinical effect of Bolin capsule combined with chemotherapy in the treatment of gastric cancer. Methods Fifty-eight gastric cancer patients were divided into chemotherapy group (n = 28) and combination group (bollen capsule plus chemotherapy group) (n = 30) according to the different therapeutic drugs. The clinical effects, appetite changes and poor appetite were compared between the two groups Reaction rate and other indicators. Results After treatment, the recent treatment in combination group was significantly better than that in chemotherapy alone group (P <0.05). After treatment, the appetite change in combination group (76.7%) was significantly better than that in chemotherapy group (14.3%, P < 0.05). The incidence of adverse reactions was 53.3% in the combination group and 50.0% in the chemotherapy group. The incidence of adverse reactions in the combination group was higher than that in the chemotherapy group (P <0.05), but there was no significant difference between the two groups > 0.05). Conclusion Bolin capsule with chemotherapy in the treatment of gastric cancer has obvious clinical curative effect in the near future. It can significantly improve the appetite condition of patients and can effectively reduce the incidence of adverse reactions in patients. The method is safe and reliable.